CCS
SGMO

Crosspoint Capital Strategies’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Crosspoint Capital Strategies’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-268,418
Closed -$44M – 78
2017
Q4 		$44M Sell
268,418
-3,458
-1% -$51.4K 3.64% 9
2017
Q3 		$4.08M Buy
271,876
+270,875
+27,060% +$2.99M 3.16% 6
2017
Q2 		$9K Buy
+1,001
New +$6.42K 0.01% 67

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Crosspoint Capital Strategies's SGMO Position: Q1 2018 in Review

Crosspoint Capital Strategies sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2018, closing a stake of 268,418 shares — an estimated $44M sold.

Crosspoint Capital Strategies first reported a position in SGMO in Q2 2017 and held it in 3 quarters. The position peaked at $44M in Q4 2017. 208 funds tracked by Wall St. Rank hold SGMO as of Q1 2018.

  • Crosspoint Capital Strategies reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2018 after selling out during the quarter.
  • Crosspoint Capital Strategies sold 268,418 SANGAMO THERAPEUTICS INC shares in Q1 2018, an estimated $44M.
  • Crosspoint Capital Strategies first reported a position in SANGAMO THERAPEUTICS INC in Q2 2017 and held it in 3 quarters.
  • Crosspoint Capital Strategies's SANGAMO THERAPEUTICS INC position peaked at $44M in Q4 2017.
  • 208 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2018.

Based on Crosspoint Capital Strategies's 13F filing for Q1 2018, filed 14 May 2018.